Skip to main content
letter
. 2020 May;8(9):596. doi: 10.21037/atm-20-2165

Table 1. Characteristics of patients with SARS-CoV-2 positive in stool test.

Characteristics Overall, mean (SD)/No. (%)
Baseline
   Age, median (IQR), y 53.00 (41.00–67.00)
   Gender (male) 5 (55.56%)
   Wuhan exposure 8 (88.89%)
   Smoking 5 (55.56%)
   Hypertension 2 (22.22%)
   Diabetes 1 (11.11%)
   Cardiovascular disease 0 (0%)
   COPD 1 (11.11%)
   Malignancy 0 (0%)
   Chronic liver disease 0 (0%)
   Fever 8 (88.89%)
   Highest temperature, °C 38.02±0.76
   Cough 5 (55.56%)
   Fatigue 7 (77.78%)
   Expectoration 4 (44.44%)
   Headache 5 (55.56%)
   Vomiting 0 (0%)
   Diarrhea 3 (33.33%)
The onset of symptom to hospital admission, d 6.56±3.61
   Systolic pressure, mmHg 127.44±23.96
   Diastolic pressure, mmHg 72.11±9.78
   Heart rate, per min 91.44±13.31
   Respiratory rate, per min 19.78±0.67
   SPO2, % 96.56±1.13
Laboratory testing
   White blood cell count, ×109/L 5.22±2.69
   Red blood cell count, ×109/L 4.34±0.87
   Neutrophil count, ×109/L 3.75±2.64
   Lymphocyte count, ×109/L 1.07±0.52
   Hemoglobin, g/L 128.56±27.58
   Platelet count, ×109/L 175.67±82.44
   Prothrombin time, s 12.19±0.71
   Activated partial thromboplastin time, s 33.59±3.28
   D-dimer, mg/L 0.40±0.28
   Alanine aminotransferase, U/L 29.15±11.01
   Aspartate aminotransferase, U/L 26.69±10.36
   Albumin, g/L 36.34±5.23
   Total bilirubin, mmol/L 10.18±2.98
   Direct bilirubin, mmol/L 3.32±1.05
   Serum K+, mmol/L 4.05±0.63
   Serum Na+, mmol/L 134.33±2.70
   Creatinine, ìmol/L (IQR) 48.30 (44.77–63.37)
   Blood urea nitrogen, mmol/L 5.46±3.21
   Lactate dehydrogenase, U/L 201.18±51.01
   Troponin T, <100 pg/mL 9 (100%)
   Creatine kinase, U/L 114.74±110.40
   Creatine kinase–MB, U/L 16.26±13.46
   Procalcitonin, ng/mL 0.09±0.07
   C-reactive protein, mg/L 31.27±20.04
   Cycle threshold of throat swab 32.95±5.58
   Cycle threshold of stool 33.68±4.46
Chest CTs findings
   Unilateral pneumonia 1 (11.11%)
   Bilateral pneumonia 5 (55.56%)
   Multiple mottling and ground-glass opacity 2 (22.22%)
Complications
   ARDS 1 (11.11%)
   Acute cardiac injury 0 (0%)
   AKI 1 (11.11%)
   Shock 0 (0%)
Treatment
   Antiviral therapy 9 (100.00%)
   Antibiotic therapy 3 (33.33%)
   Use of corticosteroid 3 (33.33%)
   Probiotics 7 (77.78%)
   CRRT 0 (0%)
Oxygen inhalation
   Nasal cannula 7 (77.78%)
   High flow 2 (22.22%)
Outcomes
   Hospitalization 7 (77.78%)
   Discharge 2 (22.22%)
   Death 0 (0%)

COPD, chronic obstructive pulmonary disease; IQR, interquartile range; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; ND, not detected; CTs, computed tomography scan; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; CRRT, continuous renal replacement therapy.